---
title: "Artelo Biosciences (ARTL) news: reverse split and delisting"
url: "https://aibio.space/companies/artelo-biosciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ARTL reverse split, delisting, going concern, offering and Nasdaq notice news: Artelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026."
---

ARTL Artelo Biosciences, Inc. NASDAQ · United States

# Artelo Biosciences (ARTL) news ARTL reverse split, delisting and going concern news

Listings · 2026-10-09

## [Artelo Biosciences flags exposure to Nasdaq's new $5,000,000 market value rule](https://aibio.space/news/artelo-biosciences-flags-exposure-nasdaqs-new-5-000-000-market-value/)

Artelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.

## Latest Artelo Biosciences news

1. 2026-08-27 Listings [Artelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026](https://aibio.space/news/artelo-biosciences-sets-1-9-reverse-split-trading-august-31-2026/) Artelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.
2. 2026-04-07 Listings [Artelo regains Nasdaq listing compliance, under one-year panel monitor](https://aibio.space/news/artelo-regains-nasdaq-listing-compliance-under-one-year-panel-monitor/) Nasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.
3. 2025-11-25 Listings [Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal](https://aibio.space/news/artelo-biosciences-gets-nasdaq-delisting-determination-stockholders/) Nasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.
4. 2025-09-30 Financings [Artelo Biosciences prices $1,999,984.67 offering at $4.40 a share](https://aibio.space/news/artelo-biosciences-prices-1-999-984-67-offering-4-40-share/) R.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.
5. 2025-07-11 Distress [Artelo Biosciences' updated 2024 statements carry auditor going-concern doubt](https://aibio.space/news/artelo-biosciences-updated-2024-statements-carry-auditor-going-concern/) MaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.
6. 2025-05-23 Listings [Artelo Biosciences gets Nasdaq notice for $652,000 stockholders' equity, below $2,500,000 minimum](https://aibio.space/news/artelo-biosciences-gets-nasdaq-notice-652-000-stockholders-equity/) The May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.

## Artelo Biosciences at a glance

- **Ticker**: ARTL

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $4.2 million

### Related companies

- [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH
- [Shuttle Pharmaceuticals Holdings](https://aibio.space/companies/shuttle-pharmaceuticals/) NASDAQ: SHPH
- [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY
- [NOVACCESS GLOBAL INC.](https://aibio.space/companies/novaccess-global/) OTC: XSNX
- [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX
- [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NASDAQ: NRXP
- [Retension Pharmaceuticals](https://aibio.space/companies/retension-pharmaceuticals/) NASDAQ: RTSN
- [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) OTC: ZVSA

### Also on NASDAQ

- [Surrozen](https://aibio.space/companies/surrozen/) SRZN
- [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) OCUL
- [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) CMPX
- [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) APRE
- [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) BRTX
- [Tempus AI](https://aibio.space/companies/tempus-ai/) TEM

## Artelo Biosciences annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$5.4 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) |
| Net income (loss) | [-$12.9 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) | [-$9.8 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) |
| Cash from operations | [-$8.5 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) |
| Cash and equivalents | [$600,000](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000368/) | [$2.3 million](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001323/) |
| Short-term investments |  | [$0](https://www.sec.gov/Archives/edgar/data/1621221/000164033425002022/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Artelo Biosciences

Did Artelo Biosciences do a reverse stock split?

Our latest story on this, dated Aug 27, 2026: "Artelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/artelo-biosciences-sets-1-9-reverse-split-trading-august-31-2026/).

Was Artelo Biosciences delisted?

Our latest story on this, dated Nov 25, 2025: "Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/artelo-biosciences-gets-nasdaq-delisting-determination-stockholders/).

Has Artelo Biosciences issued a going-concern warning?

Our latest story on this, dated Nov 25, 2025: "Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/artelo-biosciences-gets-nasdaq-delisting-determination-stockholders/).

Has Artelo Biosciences raised money recently?

Our latest story on this, dated Sep 30, 2025: "Artelo Biosciences prices $1,999,984.67 offering at $4.40 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/artelo-biosciences-prices-1-999-984-67-offering-4-40-share/).

Has Artelo Biosciences received a Nasdaq deficiency notice?

Our latest story on this, dated Jul 11, 2025: "Artelo Biosciences' updated 2024 statements carry auditor going-concern doubt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/artelo-biosciences-updated-2024-statements-carry-auditor-going-concern/).

What is the ticker symbol of Artelo Biosciences?

Artelo Biosciences, Inc. trades under the ticker ARTL on NASDAQ.

Where is Artelo Biosciences listed?

Artelo Biosciences, Inc. is listed on NASDAQ.

What is the SEC CIK of Artelo Biosciences?

The SEC Central Index Key (CIK) for Artelo Biosciences, Inc. is 1621221. Its filings are on SEC EDGAR.

How many shares does Artelo Biosciences have outstanding?

4,595,068 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Artelo Biosciences listed under?

Our directory records Artelo Biosciences, Inc. under United States.

What does Artelo Biosciences do?

Our directory classifies Artelo Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Artelo Biosciences?

The ISIN recorded for Artelo Biosciences, Inc. is US04301G8050.

Does aibio.space cover Artelo Biosciences?

aibio.space lists Artelo Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Artelo Biosciences incorporated?

SEC records list its state or country of incorporation as NV.

Is Artelo Biosciences profitable?

Artelo Biosciences, Inc. reported a net loss of $12.9 million for the fiscal year ended Dec 31, 2025, and used $8.5 million of cash in operations, per its annual report to the SEC.

## Investor discussion: Artelo Biosciences

Members talk about Artelo Biosciences (ARTL). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Artelo Biosciences, newest first. Each line links the filing it comes from.

1. 2026-10-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001665/artl_8k.htm)
2. 2026-08-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001421/artl_ex991.htm)
3. 2026-07-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001198/artl_8k.htm)
4. 2026-05-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000926/artl_424b5.htm)
5. 2026-05-15 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000903/artl_8k.htm)
6. 2026-04-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/artl_ex991.htm)
7. 2026-03-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/artl_ex991.htm)
8. 2026-03-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000461/artl_ex991.htm)
9. 2026-03-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000395/artl_ex991.htm)
10. 2026-02-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000221/artl_8k.htm)
11. 2026-02-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000227/artl_8k.htm)
12. 2026-01-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000109/artl_8k.htm)
13. 2025-11-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425002210/artl_8k.htm)
14. 2025-09-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001747/artl_424b5.htm)
15. 2025-09-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001622/artl_424b5.htm)
16. 2025-08-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001613/artl_8k.htm)
17. 2025-08-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001570/artl_8k.htm)
18. 2025-08-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001334/artl_ex991.htm)
19. 2025-07-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001239/artl_424b5.htm)
20. 2025-07-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001184/artl_ex991.htm)
21. 2025-06-26 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001062/artl_ex991.htm)
22. 2025-06-13 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425001046/artl_ex991.htm)
23. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425000935/artl_8k.htm)
24. 2025-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425000719/artl_8k.htm)
25. 2025-03-03 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1621221/000164033425000335/artl_10k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ARTL on TradingView](https://www.tradingview.com/symbols/NASDAQ-ARTL/).

## SEC filings and registration

- **SEC name**: Artelo Biosciences, Inc.

- **CIK**: 1621221

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ARTL (Nasdaq)

- **State or country of incorporation**: NV

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075

- **Phone**: 858-925-7049

- **Shares outstanding**: 4,595,068 as of 2026-08-11 (10-Q filed 2026-08-12)

- **Former names**: REACTIVE MEDICAL INC.; KNIGHT KNOX DEVELOPMENT CORP.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001665/artl_8k.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001421/artl_8k.htm) filed 2026-08-27
- [10-Q](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001323/artl_10q.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001198/artl_8k.htm) filed 2026-07-17
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1621221/000164033426001007/artl_def14a.htm) filed 2026-06-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000973/artl_8k.htm) filed 2026-05-27
- [424B5](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000966/artl_424b5.htm) filed 2026-05-26
- [424B5](https://www.sec.gov/Archives/edgar/data/1621221/000164033426000926/artl_424b5.htm) filed 2026-05-18

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001621221), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Artelo Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ARTL, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Artelo Biosciences, Inc.

- **Ticker**: ARTL

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US04301G8050

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ARTL/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/artelo-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Artelo Biosciences (ARTL) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/artelo-biosciences/